MRK – Merck & Co., Inc.
Float Short %
0.95
Margin Of Safety %
37
Put/Call OI Ratio
0.76
EPS Next Q Diff
0.08
EPS Last/This Y
1.28
EPS This/Next Y
0.67
Price
82.83
Target Price
102.19
Analyst Recom
1.96
Performance Q
1.21
Relative Volume
0.72
Beta
0.38
Ticker: MRK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | MRK | 84.25 | 0.72 | 0.25 | 768316 |
| 2025-08-18 | MRK | 84.21 | 0.75 | 0.19 | 625170 |
| 2025-08-19 | MRK | 84.97 | 0.72 | 0.47 | 641954 |
| 2025-08-20 | MRK | 84.67 | 0.75 | 0.25 | 645031 |
| 2025-08-21 | MRK | 86.14 | 0.75 | 0.45 | 655666 |
| 2025-08-22 | MRK | 87.02 | 0.75 | 0.50 | 661443 |
| 2025-08-25 | MRK | 85.33 | 0.76 | 0.97 | 638752 |
| 2025-08-26 | MRK | 85 | 0.77 | 0.38 | 669300 |
| 2025-08-27 | MRK | 84.09 | 0.76 | 0.31 | 675229 |
| 2025-08-28 | MRK | 83.39 | 0.75 | 0.64 | 684522 |
| 2025-08-29 | MRK | 84.08 | 0.74 | 0.45 | 695270 |
| 2025-09-02 | MRK | 85.48 | 0.76 | 0.70 | 678859 |
| 2025-09-03 | MRK | 84.16 | 0.77 | 0.98 | 687441 |
| 2025-09-04 | MRK | 84.04 | 0.77 | 0.31 | 691898 |
| 2025-09-05 | MRK | 84.7 | 0.73 | 0.57 | 726260 |
| 2025-09-08 | MRK | 84.16 | 0.74 | 0.52 | 703044 |
| 2025-09-09 | MRK | 84.65 | 0.74 | 0.26 | 712364 |
| 2025-09-10 | MRK | 84.1 | 0.74 | 1.25 | 716451 |
| 2025-09-11 | MRK | 85.26 | 0.74 | 1.00 | 724255 |
| 2025-09-12 | MRK | 82.84 | 0.76 | 0.11 | 737731 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | MRK | 84.24 | 50.7 | 6844.3 | 8.93 |
| 2025-08-18 | MRK | 84.20 | 50.7 | 6416.4 | 8.93 |
| 2025-08-19 | MRK | 84.93 | 50.7 | 6619.9 | 8.93 |
| 2025-08-20 | MRK | 84.66 | 50.7 | 6343.3 | 8.93 |
| 2025-08-21 | MRK | 86.13 | 50.7 | 6833.0 | 8.93 |
| 2025-08-22 | MRK | 87.36 | 50.7 | 6774.4 | 8.93 |
| 2025-08-25 | MRK | 85.33 | 50.7 | 5860.6 | 8.93 |
| 2025-08-26 | MRK | 84.99 | 50.7 | 6329.7 | 8.93 |
| 2025-08-27 | MRK | 84.08 | 50.7 | 6163.7 | 8.93 |
| 2025-08-28 | MRK | 83.25 | 50.7 | 6186.4 | 8.93 |
| 2025-08-29 | MRK | 84.12 | 50.7 | 6681.3 | 8.93 |
| 2025-09-02 | MRK | 85.47 | 50.7 | 6801.3 | 8.93 |
| 2025-09-03 | MRK | 84.18 | 50.7 | 8028.8 | 8.93 |
| 2025-09-04 | MRK | 84.03 | 50.7 | 8373.1 | 8.93 |
| 2025-09-05 | MRK | 84.71 | 50.7 | 8619.8 | 8.93 |
| 2025-09-08 | MRK | 84.09 | 50.7 | 8231.5 | 8.93 |
| 2025-09-09 | MRK | 84.62 | 50.7 | 8560.3 | 8.93 |
| 2025-09-10 | MRK | 84.04 | 50.7 | 8226.4 | 8.93 |
| 2025-09-11 | MRK | 85.15 | 50.7 | 8739.9 | 8.93 |
| 2025-09-12 | MRK | 82.83 | 50.7 | 7702.2 | 8.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | MRK | -0.84 | -0.97 | 1.04 |
| 2025-08-18 | MRK | -0.84 | -1.07 | 1.04 |
| 2025-08-19 | MRK | -0.51 | -1.07 | 1.04 |
| 2025-08-20 | MRK | -0.51 | -1.07 | 1.04 |
| 2025-08-21 | MRK | -0.17 | -1.07 | 1.04 |
| 2025-08-22 | MRK | -0.17 | -1.07 | 1.04 |
| 2025-08-25 | MRK | -0.17 | -0.95 | 1.04 |
| 2025-08-26 | MRK | -0.17 | -0.95 | 1.04 |
| 2025-08-27 | MRK | -0.17 | -0.95 | 1.02 |
| 2025-08-28 | MRK | -0.17 | -0.95 | 1.02 |
| 2025-08-29 | MRK | -0.17 | -0.95 | 1.02 |
| 2025-09-02 | MRK | -0.17 | -0.87 | 1.02 |
| 2025-09-03 | MRK | -0.17 | -0.87 | 1.02 |
| 2025-09-04 | MRK | -0.17 | -0.87 | 1.02 |
| 2025-09-05 | MRK | -0.17 | -0.87 | 1.02 |
| 2025-09-08 | MRK | -0.17 | -0.99 | 1.02 |
| 2025-09-09 | MRK | -0.17 | -0.99 | 1.02 |
| 2025-09-10 | MRK | -0.17 | -0.99 | 1.02 |
| 2025-09-11 | MRK | -0.17 | -0.99 | 0.95 |
| 2025-09-12 | MRK | -0.17 | -0.99 | 0.95 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.13
Avg. EPS Est. Current Quarter
2.37
Avg. EPS Est. Next Quarter
2.21
Insider Transactions
-0.17
Institutional Transactions
-0.99
Beta
0.38
Average Sales Estimate Current Quarter
17010
Average Sales Estimate Next Quarter
16322
Fair Value
113.17
Quality Score
97
Growth Score
83
Sentiment Score
48
Actual DrawDown %
38.5
Max Drawdown 5-Year %
-43.4
Target Price
102.19
P/E
12.77
Forward P/E
8.59
PEG
1.15
P/S
3.26
P/B
4.23
P/Free Cash Flow
14.05
EPS
6.49
Average EPS Est. Cur. Y
8.93
EPS Next Y. (Est.)
9.6
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
25.87
Relative Volume
0.72
Return on Equity vs Sector %
8.6
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
7702.2
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading